Navigation Links
Albemarle Optimizes Smallpox Drug Candidate for SIGA
Date:5/5/2008

ment with SIGA, Albemarle's Fine Chemistry Services division will scale up the manufacturing process for SIGA's active pharmaceutical ingredient (API) to produce three cGMP registration batches at Albemarle's facility in South Haven, Mich. in anticipation of pivotal human safety trials.

Albemarle has already optimized and demonstrated a process for producing ST-246 in commercial quantities using SIGA's small-scale process as a starting point, and Albemarle recently proved the optimized process at pilot plant- scale with great success under cGMP conditions. Some of this material will be used to manufacture emergency-use capsules of ST-246, according to Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer.

"Under the leadership of Dr. Shanthakumar Tyavanagimatt, SIGA's Director CMC operations & Formulations, Albemarle's R&D group have helped us flesh out a robust crystallization step that consistently delivers the most desired polymorph for this advanced API," said Dr Hruby. "Together we have developed a process that is suitable for commercial production, and can be used to create substantial quantities of the drug for stockpiling for emergency use."

"We have been very happy with the working relationship with Albemarle and the value that they have added to this important antiviral program," Dr. Hruby added.

"We are honored that SIGA has entrusted Albemarle with this significant new compound," said Dr. David Clary, Albemarle Division Vice President of Fine Chemistry Services. "Our ability to support our customers' most important and sensitive needs from pre-clinical trials into commercialization has resulted in a positive response from the pharmaceutical industry, as evidenced by the steady growth in our chemistry services business. Our success with SIGA's program underlines our proven abilities to support the chemistry needs of developing pharmaceutical companies."

New York-based SIGA Technologies applies viral and bacterial genomics
'/>"/>

SOURCE Albemarle Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...wswire/ -- Milk. It does a body good. And,now it,...ter years of,research, scientists at OncoNutritio...k that stimulate the body,s own production of anti... Release, go to:, http://www.prnewswire.com/mnr/eq...w cancer therapies, the chief scientist, Dr. David...
(Date:11/20/2008)...swire/ -- Radius Health ("Radius") announced today...ts second institutional financing round, increasin...he total amount raised since the company,s incepti...nvestors participated in the financing, led by MPM...al, The Wellcome Trust, HealthCare Ventures, Oxfor...
(Date:11/20/2008)... The Scandinavian-based drug,devel...ts of studies on its,lead antimicrobial candidate...he studies showed that the novel lytic peptidomime...ificantly better towards killing Staphylococcus,a...d standard drugs. In,addition to this it has prov...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Experimental Drug Fights Prostate Cancer 5747 1Experimental Drug Fights Prostate Cancer 5747 2Tweens double use of diabetes drugs 5745 1Tweens double use of diabetes drugs 5745 2Higher levels of pollutants found in fish caught near a coal fired power plant 5743 1Higher levels of pollutants found in fish caught near a coal fired power plant 5743 2HCA Reports Third Quarter 2007 Results 5741 1HCA Reports Third Quarter 2007 Results 5741 2HCA Reports Third Quarter 2007 Results 5741 3HCA Reports Third Quarter 2007 Results 5741 4HCA Reports Third Quarter 2007 Results 5741 5HCA Reports Third Quarter 2007 Results 5741 6HCA Reports Third Quarter 2007 Results 5741 7HCA Reports Third Quarter 2007 Results 5741 8HCA Reports Third Quarter 2007 Results 5741 9HCA Reports Third Quarter 2007 Results 5741 10HCA Reports Third Quarter 2007 Results 5741 11HCA Reports Third Quarter 2007 Results 5741 12HCA Reports Third Quarter 2007 Results 5741 13HCA Reports Third Quarter 2007 Results 5741 14
...NESS WIRE)--Mar 20, 2007 - Arrowhead,Research Corp...y-owned subsidiary Calando Pharmaceuticals has pub...Academy of Sciences,(PNAS) of the first non-human ...h Calando,s lead siRNA therapeutic candidate., Cal...eted,polymeric delivery systems and siRNA design t...
...20, 2007 /PRNewswire/ -- Treatment of,coronary art... the,inpatient setting, according to a study publi..., U.S. hospitalization rates for heart attacks (ac...from 2002 to 2005, possibly due,to broader use of ...irin, as well as declines in risk factors like smo...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:11/21/2008)... The Providence Service,...t Craig A. Norris, the Company,s,Chief Operating ... of,Directors. Mr. Norris, appointment fills the...even I. Geringer and returns the board to six memb...of the Board. , Mr. Norris, age 41, has bee...
(Date:11/21/2008)...roved effective against Lennox-Gastaut syndrome ,...new drug called Banzel (rufinamide) has been appro... of epilepsy called Lennox-Gastaut syndrome, the U... , The approval was based on results of a four-... to 30. Compared to patients who took a placebo, t...
(Date:11/21/2008).... 21 New research at W...okeless, spitless tobacco product aimed at young a...nd that RJ Reynolds, Camel Snus - touted as a soci...s surprisingly high levels of nicotine. , , ...r snuff products," said Bruce Adkins of the state ...
(Date:11/21/2008)...1 U.S. News & World...urance (NCQA) ranked BlueChoice(R) HealthPlan of S...ealth Plans(TM), published in U.S. News & Worl...ed annual ranking ranks the nation,s best health p...n and NCQA accreditation scores. NCQA and U.S. New...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...esticides and solvents can further lower fertility...udy shows these chemicals may worsen the effect of...infertility. The authors stress the findings shoul... involved a selected population of infertile men, ...
...communication has always been an effective utility...eo disc is helping patients make important decisio...ld you what treatment to have are long gone. Patie...aking process.// But sometimes this is difficult, ...
...e era where one fights battle towards eternity and...ality and morbidity indicators preclude the exista... result of such on going research , Dr. Simona Gia... Sanita, Rome, and colleagues from the MATISS Proj...
...orks better than massage as a treatment for chroni...ther therapies when used over long periods.That's ...into the effectiveness of the complementary medici... needles into special sites in the nervous system....
Other Medicine News:
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
...ing of tube racks. Its camera-based vision system ... per rack, making it ideal for use in automated se... rack to be read automatically and can be easily a...prevents a rack from being read in the wrong orien...
Polypropylene workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures a
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction
Medicine Products: